Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01185 (vasopressin)
 23,126 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The administration of 5 I. U. oxytocin (by quick infusion) or of 5 I. U. vasopressin-lysine (intramuscularly) to healthy subjects was followed by a significant decrease in the plasma non-esterified fatty acid level. We regard this as evidence of inhibition of basal lipolysis in the adipose tissue. Vasopressin also completely blocked an increase induced in the plasma non-esterified fatty acid level by activating hormone-sensitive lipase in the adipose tissue by the infusion of 0.5 mg noradrenaline.
 ...
PMID:Inhibition of lipolysis by oxytocin and vasopressin. 61 48

The peptide Z-Pro-Leu-Gly-NH2 attenuated puromycin-induced amnesia in mice when administered 5 days prior to training, while arginine vasopressin, lysine vasopressin and cyclo(Leu-Gly), were effective when given 24 hr before training. The activity of all peptides to inhibit puromycin-induced amnesia decreased as the interval after training and before peptide administration increased, suggesting that the peptides influence memory processes rather than generalized arousal mechanisms.
 ...
PMID:ADH and related peptides: effect of pre- or posttraining treatment on puromycin amnesia. 62 82

We used dDAVP, the 1-desamino-8-D arginine analogue of arginine vasopressin with high antidiuretic and low vasopressor potency, to treat 29 patients with neurogenic diabetes insipidus for up to 22 months. Intranasal dDAVP, 2.5 to 15 microgram twice daily, provided excellent control in most patients. Individual responses were independent of age, weight, and severity of diabetes insipidus. Resistance to dDAVP may be a rare complication of prolonged therapy. Two patients with acute postoperative diabetes insipidus were effectively treated with 5 microgram of dDAVP every 14 to 18 h. Compared to previous therapy, side effects of dDAVP were minimal (headaches in two patients), and control of symptoms and urine volume was as good as with vasopressin tannate in oil or better than chlorpropamide and lysine vasopressin nasal spray. We conclude that intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.
 ...
PMID:Neurogenic diabetes insipidus: management with dDAVP (1-desamino-8-D arginine vasopressin). 62 47

[Mpa1,Tyr(Et)2]-LVP (1-deamino-2-O-ethyltyrosine-8-lysine-vasopressin), [Mpa1,Tyr(n-Pr)2]-LVP, [Tyr(n-Bu)2]-LVP, [Mpa1,Tyr(n-Bu)2]-LVP, and [Mpa1,Tyr(n-hexyl)2]-LVP were synthesized in solution by the p-nitrophenyl ester method. The previously prepared [Tyr(Et)2]-LVP was resynthesized. All compounds possessed weak agonistic properties in both antidiuretic (0.5-2.0 IU/mumol) and pressor (0.5-3.0 IU/mumol) assays. In the rat none of the analogues inhibited the antidiuretic action of LVP when the two substances were given together in a single injection. However, when administered in low subthreshold doses, most of the deamino compounds suppressed the antidiuresis induced by a continuous infusion of LVP. Complete inhibition was obtained with [Mpa1,Tyr(Et)2]-LVP. The antagonistic potency seemed to decrease with increasing size of the alkyl substituent and [Mpa1,Tyr(n-hexyl)2]-LVP showed no antagonism. The molar inhibitor-LVP ratio for maximal inhibition was well below 100. Neither of the two amino analogues showed a clear-cut antagonism in the antidiuretic assay. Furthermore, none of the reported compounds was antagonistic to LVP in the rat pressor assay.
 ...
PMID:Synthesis of O-alkylated lysine-vasopressins, inhibitors of the antidiuretic response to lysine-vasopressin. 65 Jun 63

The 2-p-bromoacetylaminophenylalanine analogue of deamino-oxytoxin displayed some features of an irreversible inhibitor of oxytocin on rat uterus (long persistence of inhibitory effect, slow wash-out from the tissue). An isosteric analogue with a propionylamino group at the same position was, under similar experimental conditions, also an antagonist of oxytocin, but the features of an irreversible inhibitor were lacking. pA2 values of the two substances are between 6.5 and 6.9. The "irreversibility" of the former compound is concentration dependent and it is concluded that it cannot be entirely caused by a covalent binding of the inhibitor to the uterus receptor for oxytoxin. Like many other similar inhibitors, the substances display only an inefficient in vivo inhibition of the vasopressor effect of lysine vasopressin in rats.
 ...
PMID:Some biological properties of an "irreversible" antagonist of neurohypophyseal hormones, deamino-[Phe(4-BrCH2CONH)2]-oxytocin, and its isosteric analogue, deamino-[Phe(4-CH3CH2CONH)2]-oxytocin. 65 39

A significant elevation in plasma prolactin was observed 10 min following the intravenous injection of 100 microgram of melatonin into either estrogen-progesterone (EP) primed or into nonsteroid-treated male rats. 60 min postinjection in the EP primed rat, the groups treated with 100 microgram or 10 mg of melatonin had signficantly elevated plasma prolactin levels while no effect was observed with these same doses in the nonsteroid-treated rats. Compared to diluent-treated controls, a significant elevation in plasma prolactin was observed at 10, 20 and 60 min following the intravenous injection of either 1 microgram arginine vasotocin (AVT) or 1 mg melatonin into EP primed male rats. A consistent rise in plasma prolactin was also evident after the injection of 1 microgram of either arginine vasopressin, lysine vasopressin or AVT. Oxytocin had no effect on plasma prolactin values. The intravenous administration of 1 microgram of (deamino-1,6 dicarba, 8-arginine)-vasotocin caused a significant elevation of plasma prolactin 10 and 20 min after injection. However, the injection of another analogue of AVT, (4-leucine, 8-arginine)-vasotocin, had no effect on prolactin release at the time points measured.
 ...
PMID:Effects of melatonin and natural and synthetic analogues of arginine vasotocin on plasma prolactin levels in adult male rats. 66 73

Intrauterine pressure was recorded for 4 to 6 hours in 21 healthy women having a therapeutic abortion at 6 to 9 weeks gestation. Fourteen of the women received an intravenous injection of 300 microgram of N-alpha-triglycyl-(8-lysine)-vasopressin (TGLVP) and seven were used as controls. Uterine tone and the amplitude and duration of uterine contractions increased in all women receiving the drug, uterine tone usually rising first, with a change in contractions as a secondary effect which lasted for the rest of the observation period. Uterine activity did not change in the controls. These results suggest that TGLVP might be used for the induction of abortion during the first trimester of pregnancy.
 ...
PMID:Myometrial response to a long-acting vasopressin analogue in early pregnancy. 67 87

Somatotropic, thyrotropic, gonadotropic and corticotropic functions in 10 patients with idiopathic hypopituitary dwarfism (IH) were investigated. The patients were divided into two groups: Group I (5 patients) had normal plasma T4 levels, and Group II (5 patients) had T4 levels of less than 4.6 microgram/dl. In Group I three cases had isolated growth hormone (GH) deficiency and two cases had GH and gonadotropin (Gn) deficiencies; in Group II the 5 cases showed multiple anterior pituitary hormone deficiencies. In Group II, the plasma thyroid stimulating hormone (TSH) was 4.1-9.4 muU/ml and the response to thyrotropin releasing hormone (TRH) was greatly delayed and prolonged, with a maximum after 120 min instead of 15 min. The basal prolactin (PRL) level in Group II was 12-31 ng/ml, which was significantly higher than normal (P less than 0.001). In 4 cases in Group II, the plasma cortisol level increased 120 min after the infusion of lysine-vasopressin, whereas oral administration of metyrapone and hypoglycemia induced by insulin did not increase the plasma cortisol levels. From these findings it is concluded that hypothalamic lesions caused the pituitary hormone deficiencies in 4 Group II cases, and Group I may tentatively be differentiated from Group II by T4 determinations.
 ...
PMID:Hypothalamic-pituitary functions in patients with idiopathic pituitary dwarfism. Further evidence for hypophysiotropic human deficiencies. 67 52

This work proposes the use of (a) a commercially available homologous system AVP antibody-AVP (Arginine Vasopressin) standard and (b) new acquisitions for the improvement of sensitivity for AVP radioimmunoassay by separate or simultaneous use of two-phase sequential incubation and epsilon-aminocaproic acid (EACA). The antiserum used in the system described is very specific since none even cross-reacted with lysine vasopressin (LVP) and has an apparent affinity constant (K) of 0.909 +/- 0.047 X 10(12) l/mol. This is sufficiently high to detect 0.5 +/- 0.2 pg/tube, which is theoretically expected of biological AVP. The total assay time is less than 48 h.
 ...
PMID:A practical proposal for arginine-vasopressin radioimmunoassay. 69 31

1. Hepatic elimination of renin was measured in 10 well-compensated cardiac patients with normal liver function during a control period and during a period of reduced hepatic plasma flow, induced by physical exercise (seven patients) or intravenous infusion of lysine vasopressin (three patients). 2. Hepatic renin elimination rate (hepatic plasma flow x arterial-hepatic vein difference of plasma renin activity) was found to be linearly correlated with arterial plasma renin activity (r = 0.986, P less than 0.001). 3. When hepatic plasma flow fell by 45% the hepatic extraction ratio of renin (arterial-hepatic vein plasma renin activity difference/arterial plasma renin activity) increased by 75%. Hepatic renin clearance (hepatic plasma flow x extraction ratio) remained constant. 4. The results indicate that changes in the hepatic elimination rate of renin do not contribute to changes in plasma renin activity during these events.
 ...
PMID:Hepatic elimination of renin in man. 71 52


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>